Phase 3 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study and have signed a written consent form before any study procedures begin.
• Women between 18 and 75 years of age at the time of signing the consent form.
• People who have a good general physical functioning level, rated as fully active or restricted only in strenuous activity (confirm with trial site for exact scoring).
• People with a life expectancy of at least 3 months.
• People with cervical cancer confirmed by a tissue sample (biopsy), where the cancer cannot be cured by surgery or radiation treatment (with or without chemotherapy).
• People who have at least one measurable tumour that can be detected on a CT or MRI scan, based on standard measurement guidelines.
• People who are able to provide a tumour tissue sample — either stored from within the past 5 years or freshly collected — for testing.
• People whose blood test results during the screening period show that the heart, liver, kidneys, and other organs are working well enough to participate.
• Women who could become pregnant must use effective contraception from the time of signing consent until 180 days after the last dose of the study drug.

Who may not be able to join:

• People whose cervical cancer is a less common type, such as small cell carcinoma, clear cell carcinoma, or sarcoma.
• People who have previously received certain targeted cancer therapies, including anti-angiogenic drugs (such as bevacizumab), immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies), or other treatments that work on the immune system's response to tumours.
• People who have an active autoimmune disease, or one that may come back.
• People who have had another active cancer within the 3 years before joining the trial.
• People who have taken part in another clinical trial or received another experimental treatment within 4 weeks before joining.
• People who have had major surgery, an open biopsy, or a significant injury within 4 weeks before joining, or who are expected to need major surgery during the trial.
• People who have received any anti-cancer treatment within 4 weeks before joining.
• People who have had a serious infection within 4 weeks before joining.
• People who have received a vaccination within 4 weeks before joining.
• People who have taken immune-modifying medicines (such as thymosin, interferon, or interleukin-2) within 2 weeks before joining.
• People who have used antibiotic, antiviral, or antifungal medicines taken throughout the body (not just topically) within 2 weeks before joining.
• People who need ongoing treatment with higher-dose steroid medicines or other medicines that suppress the immune system, within 2 weeks before joining (confirm with trial site for exact dose thresholds).
• People who have a significant kidney blockage (hydronephrosis) that cannot be relieved by medical procedures.
• People whose cancer has spread to the brain or the lining around the brain and spinal cord.
• People who have uncontrolled fluid build-up around the lungs, heart, or abdomen that requires draining more than once a month.
• People known to have a primary or secondary immune deficiency condition, including a positive HIV test result.
• People who have previously received a transplanted organ or bone marrow/stem cells from another person.
• People with known active tuberculosis or active syphilis infection.
• People with a known history of severe allergic reactions to monoclonal antibody medicines.
• People with known allergies or medical reasons preventing the use of cisplatin, carboplatin, or paclitaxel (chemotherapy drugs used in this trial).
• People who have, or have had, certain lung conditions — such as interstitial lung disease or significant loss of lung function — that could make it hard to detect or manage potential lung side effects from the study drug.
• People with active hepatitis B or C virus infection, or hepatitis B carriers with virus levels above a certain threshold in their blood (confirm with trial site for exact levels).
• People with active or previously diagnosed inflammatory bowel disease.
• People who have had certain serious heart or blood vessel conditions, including heart attack, unstable chest pain, blood clots, or other major cardiovascular events within 6 months before joining; moderate to severe heart failure; serious heart rhythm problems requiring medication; or reduced heart pumping function below a certain level (confirm with trial site for details).
• People with moderate or severe nerve damage in the hands or feet (peripheral neuropathy).
• People who have not yet recovered from side effects of a previous cancer treatment.
• Women who are pregnant or breastfeeding.
• People with any other serious illness or condition that the trial doctors believe could put them at risk or affect the reliability of the trial results.
• People with known allergies or medical reasons preventing the safe use of bevacizumab or any of its ingredients.

Important: Always verify eligibility with the trial site directly before applying.